Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1985 1
1986 1
1988 2
1989 5
1990 8
1991 6
1992 4
1993 9
1994 10
1995 8
1996 14
1997 10
1998 35
1999 41
2000 45
2001 39
2002 63
2003 66
2004 77
2005 56
2006 76
2007 73
2008 54
2009 65
2010 55
2011 64
2012 63
2013 61
2014 52
2015 79
2016 65
2017 56
2018 61
2019 61
2020 58
2021 67
2022 82
2023 66
2024 104
2025 125
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,766 results

Results by year

Citations

9 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. The main class of drugs currently used for the treatment of AD are acetylchol …
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of co …
Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis.
Gao Y, Liu Y, Li Y. Gao Y, et al. Adv Clin Exp Med. 2024 Nov;33(11):1179-1187. doi: 10.17219/acem/176051. Adv Clin Exp Med. 2024. PMID: 38439609 Free article.
Alzheimer's disease (AD) affects millions of people worldwide. The most commonly used drugs are acetylcholinesterase inhibitors, i.e., donepezil, galantamine and rivastigmine, which increase levels of acetylcholine. However, the exact efficac …
Alzheimer's disease (AD) affects millions of people worldwide. The most commonly used drugs are acetylcholinesterase …
Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Birks J. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article.
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). ...Fewer patients suffer adv …
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of eac …
A 2025 update on treatment strategies for the Alzheimer's disease spectrum.
Wu CK, Fuh JL. Wu CK, et al. J Chin Med Assoc. 2025 Jul 1;88(7):495-502. doi: 10.1097/JCMA.0000000000001252. Epub 2025 May 30. J Chin Med Assoc. 2025. PMID: 40442885 Free PMC article. Review.
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging from preclinical/asymptomatic phase to severe dementia. ...Cholinesterase inhibitors and memantine remain the standard treatments …
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging fro …
Cholinesterase inhibitors as Alzheimer's therapeutics (Review).
Sharma K. Sharma K. Mol Med Rep. 2019 Aug;20(2):1479-1487. doi: 10.3892/mmr.2019.10374. Epub 2019 Jun 11. Mol Med Rep. 2019. PMID: 31257471 Free PMC article. Review.
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic syndrome of the central nervous system that causes a decline in cognitive function and language ability. ...Currently, the available drugs for AD are predominantly cholin …
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic syndrome of the central nervous s …
Alzheimer's disease and its treatment by different approaches: A review.
Srivastava S, Ahmad R, Khare SK. Srivastava S, et al. Eur J Med Chem. 2021 Apr 15;216:113320. doi: 10.1016/j.ejmech.2021.113320. Epub 2021 Feb 23. Eur J Med Chem. 2021. PMID: 33652356 Review.
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability development and interrupts neurocognitive function. ...In the biomedical sciences, effective treatment for Alzheimer's disease is a severe obstacle. Ther …
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability development and interrupts neuroco …
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article.
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. ...Results are conflicting; two studies suggest no differences in efficacy between compared drugs, while one …
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galanta …
Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
Sabbagh M, Sadowsky C, Tousi B, Agronin ME, Alva G, Armon C, Bernick C, Keegan AP, Karantzoulis S, Baror E, Ploznik M, Pascual-Leone A. Sabbagh M, et al. Alzheimers Dement. 2020 Apr;16(4):641-650. doi: 10.1016/j.jalz.2019.08.197. Epub 2020 Jan 16. Alzheimers Dement. 2020. PMID: 31879235 Clinical Trial.
INTRODUCTION: This clinical trial evaluates the efficacy and safety of a 6-week course of daily neuroAD therapy. METHODS: 131 subjects between 60 and 90 years old, unmedicated for Alzheimer's disease (AD), or on stable doses of an acetylcholinester …
INTRODUCTION: This clinical trial evaluates the efficacy and safety of a 6-week course of daily neuroAD therapy. METHODS: 131 subjec …
Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors.
Saxena M, Dubey R. Saxena M, et al. Curr Top Med Chem. 2019;19(4):264-275. doi: 10.2174/1568026619666190128125912. Curr Top Med Chem. 2019. PMID: 30706815 Review.
Alzheimer's Disease (AD), affecting a large population worldwide is characterized by the loss of memory and learning ability in the old population. The enzyme Acetylcholinesterase Enzyme (AChE) is the key enzyme in the hydrolysis of the neurotransmitte …
Alzheimer's Disease (AD), affecting a large population worldwide is characterized by the loss of memory and learning ab …
The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis.
Hsu CW, Hsu TW, Kao YC, Lin YH, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Yang FC, Tsai CK, Yu CL, Tu YK, Liang CS. Hsu CW, et al. J Prev Alzheimers Dis. 2025 Sep;12(8):100195. doi: 10.1016/j.tjpad.2025.100195. Epub 2025 May 1. J Prev Alzheimers Dis. 2025. PMID: 40316479 Free PMC article.
BACKGROUND: To date, studies have not compared the efficacy and safety of monoclonal antibodies (mABs) with acetylcholinesterase inhibitors (AChEIs). ...The primary outcome was change in cognitive function, measured by the Alzheimer's Disease …
BACKGROUND: To date, studies have not compared the efficacy and safety of monoclonal antibodies (mABs) with acetylcholinesterase …
1,766 results